Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.48 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 2/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CDA | P32320 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26369647 | 1.00 | PYGM (0.48) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL104679 | 1.00 | PYGM (0.48) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17721687 | 0.90 | PYGM (0.47) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18512960 | 0.89 | PYGM (0.58) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL41270 | 0.89 | PYGM (0.58) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL63573 | 0.89 | PYGM (0.58) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL14853731 | 0.89 | PYGM (0.58) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18573807 | 0.89 | PYGM (0.58) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18503558 | 0.89 | PYGM (0.58) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL3805743 | 0.88 | PYGM (0.45) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18360 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4659246-A1 | ELECTROCHEMICAL SYNTHESIS WITH REDOX STABLE NUCLEOTIDES | Atlas Data Storage, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250368986-A1 | ELECTROCHEMICAL SYNTHESIS WITH REDOX STABLE NUCLEOTIDES | ATLAS DATA STORAGE INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250304965-A1 | DOUBLE-STRANDED RNA MOLECULE AND PHARMACEUTICAL USE THEREOF | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-10-02 | — | — | US | claimed |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2025-09-25 | — | — | US | claimed |
| US-20250277223-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES | IMCYSE SA (BE) | 2025-09-04 | — | — | US | claimed |
| EP-4598935-A2 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| US-6706691-B1 | BIOAVAILABILITY OF COMPOSITIONS METABOLIZED BY THE GUT P450 ISOZYMES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-03-16 | — | — | US | claimed |
| EP-1308511-A1 | Use of angiopoietin-like 1 and angiopoietin-like 2 nucleic acids and proteins for the treatment of blood-related disorders and defects in vasculature. | Mermaid Pharmaceuticals GmbH (DE) | 2003-05-07 | — | — | EP | claimed |
| EP-1295130-A2 | NIMR COMPOSITIONS AND THEIR METHODS OF USE | TRUSTEES OF TUFTS COLLEGE (US) | 2003-03-26 | — | — | EP | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| WO-2001070776-A2 | NIMR COMPOSITIONS AND THEIR METHODS OF USE | TRUSTEES OF TUFTS COLLEGE (US) | 2001-09-27 | — | — | WO | claimed |
| US-5998596-A | Inhibition of protein kinase activity by aptameric action of oligonucleotides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-07 | — | — | US | claimed |
| WO-1998042723-A9 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS | — | 1999-03-04 | — | — | WO | claimed |
| EP-0795029-A1 | CHEMICAL LABELLING OF OBJECTS | Pabio (NO) | 1997-09-17 | — | — | EP | claimed |
| WO-1996017954-A1 | CHEMICAL LABELLING OF OBJECTS | PABIO (DK) | 1996-06-13 | — | — | WO | claimed |
| US-5486603-A | Oligonucleotide having enhanced binding affinity | GILEAD SCIENCES, INC. (US) | 1996-01-23 | — | — | US | claimed |